Last reviewed · How we verify

NCT06627972: ALIGCF

Asprosin Level in Individuals With Periodontal Disease

Completed Last updated 4 October 2024
What this trial tests

trial in Periodontitis in 75 participants. Completed in 31 August 2022.

Timeline
1 January 2022
Primary endpoint
31 July 2022
31 August 2022

Quick facts

Lead sponsorMustafa Kemal University
StatusCompleted
Study typeOBSERVATIONAL
Enrollment75
Start date1 January 2022
Primary completion31 July 2022
Estimated completion31 August 2022
Sites1 location across Turkey (Türkiye)

Conditions studied

Sponsor

Mustafa Kemal University

Who can join

Adults 18 to 45, any sex, with Periodontitis or Periodontal Health. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The aim of this study was to investigate the levels of asprosin hormone and tumour necrosis factor alpha (TNF-α) in gingival crevicular fluids and to compare its level with those in saliva and serum in patients with gingivitis and periodontitis.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

  1. Is there a relationship between periodontal conditions and asprosin levels in gingival crevicular fluid, saliva and serum?
    Tutuş S, Tanık A, Arpağ OF, Önderci M. · · 2025 · cited 2× · PMID 40301876 · DOI 10.1186/s12903-025-06014-1

Verify or expand the search:

Other recruiting trials for Periodontitis

Currently open trials in the same condition.

Other Mustafa Kemal University trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06627972.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing